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Abstract 
Induced pluripotent stem (iPS) cells that are functionally comparable to embryonic stem (ES) 
cells can be generated from somatic cells by introducing the four transcription factors Oct4, 
Sox2, Klf4, and c-Myc using retroviruses. Given that iPS cell technology may be useful for 
medical applications, the quality of iPS cells needs to be maintained during prolonged 
cultivation. However, it is unclear whether there are any differences in the quality of 
stability among different iPS clones. Here, I report the efficient selection of stable iPS cells. 
The iPS colonies that underwent retroviral silencing on day 14 (called early iPS) were more 
stable than those silenced on day 30 (called late  iPS) in terms of morphology and karyotype. 
My early iPS cells expressed pluripotency marker genes and showed proliferation efficiency 
similar to ES cells. Furthermore, they gave rise to adult chimeras and could show germline 
competency when injected into blastocysts or eight-cell-stage mbryos. In contrast, the late 
iPS cells tended to lose their ES cell-like morphology and normal karyotype in long-term 
culture. This study is a critical step towards optimizing the iPS technology that can be 
available for medical applications. 
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General Introduction 
Derivation of ES cells 
      Pluripotent stem cells can self-renew and generate all cell types of the body. A 
major example of pluripotent stem cells is embryonic stem (ES) cells, which are derived from 
the inner cell mass of blastocysts  [1-3]. ES cells express pluripotency marker genes uch as 
Oct4 (also called  Oct3/4 or  Pou5f1), Sox2, and Nanog, and differentiate into all three 
(endoderm, esoderm, and ectoderm) germ layers in vitro. Furthermore, mouse and human 
ES cells form teratomas when injected into immune-deficient mice, and mouse ES cells give 
rise to adult chimeras and contribute to germline transmission when microinjected into 
eight-cell-stage embryos or blastocysts. Therefore, ES cells are considered to provide an 
attractive source in regenerative medicine and developmental biology. When ES cells are 
utilized for transplantation therapy, however, there are two problems: (i) the derivation of ES 
cells requires fertilized eggs and developing embryos and (ii) the use of other people's ES 
cells could result in immunological rejection. To avoid these issues, it would be important 
to obtain pluripotent s em cells without using others' embryos. 
Nuclear transfer 
      The first nuclear transfer experiments, which involved the transfer of the nuclei nto 
enucleated oocytes, were performed using frog in order to examine whether the nuclei of 
differentiated cells are equivalent to those of embryonic ells [4, 5]. These studies howed 
that adult cells could be reprogrammed into pluripotent cells. In 1997, the mammal was first 
cloned from follicle cells by the generation of the sheep "Dolly" [6]. Furthermore, mice 
                           4
were produced from lymphoid cells albeit with two-step method that involved the generation 
of ES cells derived from cloned embryos [7]. Cloned animals from ES cells and neural stem 
cells were more efficiently generated than that from the terminally differentiated lymphocytes 
 [8]. Therefore, it has been suggested that undefined factors that regulate the reprogramming 
may exist in the oocytes, and that the differentiation state of the donor cells may affect 
reprogramming efficiency  [9]. More recently, the strategy that did not require the oocytes 
was reported; pluripotent cells were produced by nuclear transfer using adult cells and 
zygotes in mouse  [10]. Given that it is difficult to obtain unfertilized human oocytes, this 
strategy might be applicable to human system and major practical concerns would be solved 
[9]. Nevertheless, however, an ethical problem is that nuclear transfer strategy requires 
unfertilized or fertilized eggs. 
Cell fusion 
      Mouse somatic nuclei were reprogrammed into the pluripotent state by another 
strategy, which is cell fusion of somatic cells with embryonic cells. The pluripotency was 
shown by fusion or electrofusion of thymocytes with embryonic carcinoma cells or ES cells 
[11,  12]. When the fused cells were transplanted into immune-deficient mice, teratomas 
consisting tissues from all three germ layers were obtained, indicating that the pluripotency of 
the cells is dominant. Reprogramming by cell fusion with human ES cells was also 
demonstrated  [13,  14]. Furthermore, it has been reported that nuclear factors may be 
responsible for reprogramming by cell fusion  [15]. There was a possibility that transcription 
factors important for the pluripotency might be involved in the nuclear factors, given that the 
fusion of neural stem cells with ES cells that overexpressed Nanog dramatically increased the 
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number of reprogrammed cell colonies  [16]. It has also been reported that self-renewal of 
mouse ES cells in the absence of leukemia inhibitory factor can be undergone by Nanog 
overexpression and that Nanog knockout ES cells differentiate spontaneously [17,  18]. 
However, the mechanisms underlying reprogramming remain elusive and cell fusion strategy 
requires ES cells. 
Generation of iPS cells 
      Yamanaka and colleagues hypothesized that transcription factors expressed in ES 
cells might have the ability to reprogram somatic cells into pluripotent stem cells. They 
tested 24 candidate factors in reprogramming of mouse fibroblasts and demonstrated the 
technology to "directly" reprogram mouse somatic cells into pluripotent stem cells. In 2006, 
they found that retroviral introduction of the transcription factors  Oct4, Sox2, Klf4 , and c-Myc 
into mouse fibroblasts and the selection for  Fbx15 expression resulted in the derivation of 
induced pluripotent stem (iPS) cells that were similar to ES cells regarding morphology, 
proliferation efficiency, and teratoma formation while DNA methylation profiles of the iPS 
cells were different from those of ES cells [19]. Furthermore,  Fbx15 iPS cells did not 
express endogenous Oct4, Sox2, and Nanog or expressed them at lower levels than those of 
ES cells. When transplanted into blastocysts, the  iPS cells could contribute chimeric 
embryos but not adult mice and germline competency. These observations indicated that 
 Fbx15 iPS cells were not fully reprogrammed. Further experiments howed that mouse iPS 
cells capable of contribution to adult chimeras could be obtained from genetically unmodified 
fibroblasts  [20], suggesting that selection markers are important for the generation of 
completely reprogrammed iPS cells. 
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      Expressions of the essential pluripotency genes Oct4 and Nanog were used as a 
selection marker of mouse  iPS cells [21, 22]. In contrast o  Fbx15 iPS cells, Oct4 iPS and 
Nanog iPS cells showed the characteristics comparable to those of ES cells in terms of 
pluripotency genes expression, DNA demethylation patterns of endogenous Oct4 and Nanog 
promoter regions, and contribution to viable chimera and germline competency. This 
indicated that Oct4- or Nanog-selected  iPS cells were fully reprogrammed ones and that 
activation of Oct4 or Nanog was more stringent selection marker than that of  Fbx15. 
Different copy numbers of viral transgenes in one iPS clone were detectable, meaning that 
proper expression levels required for the generation of fully reprogrammed iPS cells is 
unclear. It is possible that relative expression levels of the individual factors are crucial for 
complete reprogramming. Moreover, retroviral silencing of the four factors was observed in 
Oct4 iPS and Nanog iPS cells but not in  Fbx15 iPS cells. The data suggest hat iPS cells 
with silenced retroviral factors are fully reprogrammed, which is consistent with a previous 
study that retroviral expression is silenced in early embryonic cells due to the 
methyltransferases activation [23]. Therefore, retroviral silencing is one of important 
criteria in the pluripotent state. 
      Human fibroblasts were reprogrammed into iPS cells by expression of Oct4 and 
Sox2, combined with either Klf4 and c-Myc or Lin28 and Nanog  [24-27]. Human iPS cells 
were similar to ES cells regarding gene expression, proliferation efficiency, methylation 
patterns of promoter regions of Oct4 and Nanog, and teratoma formation. Induction 
efficiency of human iPS cells was lower than that of mouse iPS cells. Furthermore, 
reprogramming of human somatic cells was a gradual process compared to that of mouse cells. 
Recently, more rapid and efficient reprogramming was reported using human keratinocytes 
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 [28], demonstrating that donor cell type is an important factor for the iPS cell production. 
      These studies indicate that iPS cells could provide a resource for in vitro usage, 
including drug screening and disease modeling  [29-31], and cell transplantation therapy. 
Given the medical applications of iPS cell technology, it will be necessary to efficiently 
generate stable iPS cells that can maintain the pluripotency during long-term cultivation. 
Although different iPS clones with silenced retroviral trasgenes are observed in both mouse 
and human iPS cell induction, it is not clear whether these clones have different quality of 
stability. 
Retroviral silencing in the pluripotent state 
 Fbx15-selected iPS cells continue to express retroviral genes and Oct4- or 
Nanog-selected iPS cells do not, indicating that iPS cells with or without silenced retroviral 
factors are obtained during reprogramming of somatic cells. It is known that iPS cell-like 
colonies begin to express endogenous Oct4, Sox2, and Nanog on around day 10 after 
infection of Oct4, Sox2, Klf4, and c-Myc retroviruses. This provides a possibility that 
expression of these four transcription factors may be required only for initial expression of 
endogenous Oct4, Scx2, and Nanog, and that activation of methyltransferases Dnmt3a and 
Dnmt3b associated with retroviral silencing [23] may be detectable at early stage of 
reprogramming. It is also possible that donor somatic cells may undergo retroviral silencing 
after the cells are fully reprogrammed, considering that retroviruses are strong targets for 
silencing in early embryonic ells. 
      Oct4 iPS and Nanog iPS cells can maintain their pluripotency without expression of 
the exogenous factors, and excess expression of the retroviral genes could cause 
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differentiation of pluripotent cells, meaning that observation of retroviral silencing is 
important for the generation of iPS cells. Total amounts of exogenous and endogenous 
genes are a critical factor for maintenance of the pluripotency, and thus iPS cells with silenced 
viral genes may show the characteristics imilar to ES cells. Furthermore, endogenous 
pluripotency genes can be expressed by transcriptional activation of retroviral genes but these 
viral genes may not be silenced by activation of endogenous Oct4, Scx2, and Nanog, given 
that retroviral silencing occurs due to epigenetic modification. In addition, retrovirus 
elements including the region of long terminal repeat may result in increase the risk of tumor 
formation. Therefore, retroviral silencing can be one of important criteria for the 
establishment of fully reprogrammed iPS cells that can maintain the pluripotency (Fig. 0). 
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Figure 0. The significance of retroviral silencing in  iPS cell generation. 
(A) In donor somatic cell, endogenous pluripotency genes such as  Oct4,  Sox2, and  Nanog are 
expressed by transcription activation of Oct4,  Sox2, Klf4, and c-Mvc retroviruses. 
(B) When donor cell is reprogrammed into ES-like cell, total expression of pluripotency genes needs 
to be conserved in order to maintain the pluripotency. 
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Introduction 
Toward medical applications of iPS cells 
      Mouse iPS cells were produced from fibroblasts using Oct4, Sox2, Klf4, and c-Myc 
retroviruses  [19]. Although Oct4 and Sox2 genes are known to be required for maintenance 
of pluripotency, the roles of Klf4 and c-Myc in somatic cell reprogramming are not fully 
understood. Given that L-Myc could be used instead of c-Myc in iPS cell production [32], 
transformation of donor cells may not be essential for reprogramming. c-Myc was 
dispensable for mouse cell reprogramming but was crucial for rapid and efficient generation 
of germline transmittable iPS cells  [33]. The proto-oncogene c-Myc caused tumor formation 
in iPS cell-derived chimeric mice and their offspring [22]. Thus, the use of c-Myc as a 
reprogramming factor enhances both iPS cell derivation and tumor formation. Retrovirus 
results in higher reprogramming efficiency than that obtained using other factor delivery 
methods reported to date while other reprogramming methods uch as adenoviruses [34, 35], 
plasmid vectors [36], and recombinant proteins [37,  38] have been studied. In the generation 
of iPS cells with retroviruses, fully reprogrammed iPS cells silenced retroviral expression, 
whereas incompletely reprogrammed cells continued to express the viral transgenes  [22]. 
Therefore, retroviral silencing is a key feature for the pluripotent state  [9,  39]. Moreover, it 
is reported that the expression of the four exogenous factors Oct4, Sox2,  K1f4, and c-Myc is 
required for at least 10 to 12 days during the reprogramming of mouse fibroblasts [40,  41], 
and some iPS clones begin to undergo retroviral silencing on around day 10 after infection of 
the four factors [42]. It is likely that there may be a correlation between the timing of 
endogenous pluripotency marker expression and viral silencing. At least in mouse iPS cell 
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induction, retroviral silencing occurred at different time points in individual iPS clones [42]. 
However, little is known about differences in the quality of stability among different  iPS 
clones undergoing retroviral silencing. If iPS colonies, which silenced viral expression or 
expressed endogenous Oct4 or Nanog, lose the pluripotency during several passages, the cells 
are not superior and useful for medical applications in vitro and in vivo. Thus, it is important 
to determine fficient methods for stable iPS cell generation. 
Retroviral silencing in iPS cell generation 
      Expression levels of individual pluripotency genes and relative amounts of these 
genes may be important for maintenance and induction of the pluripotency. For example, in 
ES cells, upregulation of Oct4 resulted in spontaneous differentiation into primitive endoderm 
and mesoderm, and down regulation of Oct4 caused differentiation into trophectoderm [43]. 
In  iPS cell induction using retroviruses, although endogenous Oct4 is one of target genes of 
retroviral transcription factors, it does not regulate the expression of retroviral transgenes. If 
viral genes continue to express after endogenous Oct4 activation required for maintenance of 
pluripotency, iPS cells could differentiate into endoderm and mesoderm due to excess 
expression of Oct4. Alternatively, if viral silencing occurs before sufficient activation of 
endogenous Oct4, fully reprogrammed iPS cells could not be generated. Therefore, timing 
of retroviral silencing would be important for iPS cell derivation. Furthermore, 
incompletion of retroviral silencing could result in increase of tumor formation risk and might 
prevent epigenetic regulation such as DNA demethylation in treated cells. In this study, the 
quality of stability of different iPS clones that silenced the retroviral genes was examined. 
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Materials and Methods 
Cell culture 
      Mouse embryonic fibroblasts (MEFs) and adult tail tip fibroblasts (TTFs) were 
isolated from E13.5  C57BL/6 embryos and adult  C57BL/6 mice (6-7 weeks of age), 
respectively. MEFs and TTFs were cultured in medium containing Dulbecco's modified 
eagle medium (DMEM, Sigma-Aldrich) with 10% fetal bovine serum (FBS, Invitrogen), 50 
units penicillin, and 50  in  m1-1 streptomycin.  C57BL/6 ES cells were obtained from 
American Type Culture Collection (SCRC-1002, ATCC). ES and iPS cells were maintained 
in ES medium  [Knockout DMEM (Invitrogen) with 20% Knockout Serum Replacement 
(Invitrogen), 2 mM L-glutamine, 100  tiM nonessential amino acids, 100  iuM 
beta-mercaptoethanol, 1000 units  m1-1 leukemia inhibitory factor (LIF), 50 units  m1-1 
penicillin, and 50  [ig  ml-1  streptomycin] on feeder cells as previously described  [42]. These 
culture media were replaced every day. 
Feeder cells 
      MEFs at passage 2-4 were cultured on 0.15% gelatin until the cells became 90% 
confluent. Then, 12  !,tg  m1-1 mitomycin-C (Kyowa-Kirin, Japan) was added and the cultures 
were incubated for 2.5 h at 37°C and 5%  CO2. The cells were washed two times with 
phosphate-buffered saline (PBS) and cultured in medium containing DMEM with 10% FBS, 
50 units  m1-1 penicillin, and 50  µg  m1-1 streptomycin. 
Reprogramming 
 Plat-E packaging cells and the pMX retroviral vectors (Oct4,  Sox2  ,Klf4 , and c-Myc) 
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were obtained from Addgene. Plat-E cells were cultured in medium containing DMEM with 
10% FBS, 50 units  m1-1 penicillin, and 50  tug  m1-1 streptomycin with 1  ug  m1-1 puromycin 
(Sigma-Aldrich) and 1  ug  m1-1 blastcidine S (Funakoshi, Japan). Retroviral infection for iPS 
cell generation was performed as previously described by other reports  [19, 44, 45] with 
minor modifications. MEFs and adult TTFs were infected with viral supernatants generated 
from transfection (FuGENE 6, Roche) of Plat-E cells with the pMXs. On the next day, the 
infected MEFs and TTFs (3,000 cells) were re-seeded into ten 10-cm dishes with feeders. 
The cells were subsequently cultured in ES medium. 
Reverse transcription-polymerase chain reaction (RT-PCR) 
      Total RNA was isolated with TRIZOL (Invitrogen), and first-strand cDNA synthesis 
was performed using SuperScript III reverse transcriptase (Invitrogen), according to the 
manufacturer's instructions. PCR was performed with KOD plus (Toyobo, Japan) and the 
products were resolved by electrophoresis with TAE based gel containing 2% agarose. 
Immunofluorescence 
      iPS cells were fixed in 4% paraformaldehyde for 15  min at 25°C, washed three 
times with PBS, and blocked for 20  min in PBS containing 5% FBS and 0.1% Triton X-100 
(Sigma-Aldrich). Primary antibodies against Oct4 (SC-5279, Santa Cruz) or Nanog 
 (RCAB0001P,  ReproCELL, Japan) in PBS containing 1% FBS and 0.1% Triton  X-100 were 
applied for 1 h at 25°C. After washing three times with PBS, secondary antibodies were 
applied for 1 h at 25°C. 
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Alkaline phosphatase staining 
      Each iPS clone(1 x  105 cells) was seeded into a well of a six-well plate with feeder 
cells. Two days later, cells were stained using an alkaline phosphatase kit (Sigma-Aldrich), 
according to the manufacturer's instructions. 
Karyotyping 
      Karyotyping was performed as described by Longo et al.  [46] with some 
modifications. Slides were washed with detergent and rinsed in 70% ethanol. iPS cells (4 
 x105 cells in 2 ml of ES medium) were seeded into a well of a gelatin-coated six-well plate. 
On the next day, 20  I,d of colcemid solution (15210-040, Invitrogen) was added and the 
culture was incubated for 1.5 h at 37°C and 5%  CO2. The cells were washed with PBS, 
harvested by trypsinization, and centrifuged. The pellet was washed with PBS and 
resuspended gently in 1 ml of 1% (wt/vol)  tri-sodium citrate solution (SCS). One milliliter 
of SCS was added, and the tube was inverted twice.  An additional 6 ml of SCS was added, 
the tube was inverted twice, and was left for 5  min at room temperature (RT). After 
centrifugation, 7 ml of supernatant was discarded and the pellet was resuspended gently two 
times in the remaining 1 ml of SCS. Five drops of fixative (1:3 acetic acid:methanol) were 
added and the cells were resuspended. Seven milliliters of fixative was added, the tube was 
vigorously inverted 10 times, and incubated for 15  min at RT (with one inversion during the 
incubation). The cells were centrifuged, resuspended in 7 ml of fixative, and centrifuged 
again. Six milliliters of supernatant was removed and the cells were resuspended in the 
remaining 1 ml of fixative. 
      The slideswere put over a water bath at 37°C. The cells (5-10 drops) were put 
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onto the slides and exposed for 1  min to steam. The air-dried samples were stained with 
Hoechst 33342 (Invitrogen) and observed using fluorescent microscopy  (400  x  ). Seven 
chromosomal spreads were counted and if the number of spreads with a normal karyotype of 
40 chromosomes was less than four (or 70%), an additional four spreads were counted. The 
ratio of cells with a normal karyotype was calculated from seven or eleven spreads for each 
iPS clone. 
Generation of chimeras 
       Two-cell-stage mouse embryos derived from ICR mice were flushed and cultured in 
Hepes-buffered potassium simplex optimized medium (KSOM) until the eight-cell-stage or 
early blastocyst stage. iPS cells (6-10 cells) were microinjected into eight-cell-stage 
embryos or blastocysts. The eight-cell-stage mbryos were cultured until the blastocyst 
stage. These blastocysts were transplanted into the uterine horns of pseudo-pregnant ICR 
recipients. Chimerism was estimated by coat color contribution. Male Chimeras derived 
from C57BL/6 (black coat color) iPS cells were mated with ICR (white color) females and 
 germline transmission of iPS cells was indicated by obtaining offspring with black or agouti 
coat color. 
Statistical analysis 
      Thestudent's t test (two-tailed) was used for all statistical analyses. 
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Results 
Induction of  iPS colonies 
      I first assessed the effects of retroviral silencing on gene expression in induced 
colonies. I infected MEFs using retroviruses expressing Oct4, Sox2, Klf4, c-Myc, and green 
fluorescent protein (GFP). I obtained morphologically ES cell-like and GFP-negative or 
GFP-positive colonies (passage 0). I randomly picked two GFP-negative and four 
GFP-positive colonies on day 13 after viral infection (Fig.  1A), and performed reverse 
transcription-polymerase chain reaction (RT-PCR) analysis at passage 3 (Fig. 1B). GFP 
colonies expressed pluripotency marker genes at levels similar to those in ES cells. In 
contrast,  GFP+ colonies failed to express these markers or expressed them at extremely low 
levels. Furthermore,  GFP colonies lost the expression of all of the transgenes whereas 
 GFP+ colonies still expressed them, indicating that the lack of exogenous GFP expression 
reflects retroviral silencing. These data suggest hat superior iPS clones can be efficiently 
obtained from GFP colonies.
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Figure 1. Morphology and gene expression of induced colonies. 
(A) Morphology and GFP fluorescence images. GFP-negative and GFP-positive colonies are shown. 
(B) RT-PCR analysis. The expression of ES cell markers and transgenes in six clones at passage 3 
(two GFP-negative and four GFP-positive clones) was examined. ES cells were used as a control.
Stability in morphology of iPS clones 
      We previously reported that individual ES cell-like colonies underwent retroviral 
silencing at different time points, when published culture conditions were used for 
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reprogramming of mouse fibroblasts [42]. In the present study, I hypothesized that different 
ES cell-like colonies with silenced retroviral GFP might show different quality; I therefore 
asked whether the timing of retroviral silencing marks the stability of iPS cells. I infected 
MEF and adult TTF cells derived from  C57BL/6 mice with retroviruses encoding the four 
factors and GFP (Fig. 2A). On the next day, I re-seeded the MEFs and TTFs onto feeder 
cells. I marked ES cell-like and GFP-positive colonies on day 6, and followed GFP 
expression every day using fluorescent microscopy. I then attempted to divide the induced 
colonies into two groups: ES cell-like colonies that underwent retroviral silencing (i) on 
around day 14 (called early iPS) or (ii) on around day 30 (called late iPS), after infection. 
Indeed, I picked colonies on days 11-14 or 29-34, when GFP-negative colonies were induced 
from GFP-positive ones (Fig. 2A and Table 1). 
      I expanded these clones and continued monitoring their morphology for up to 20 
passages (Fig. 2B-E and Table 1). I found a significant difference in the stability of early 
and late iPS clones. That is, I observed that 21 of 25 early MEF iPS clones maintained ES 
cell-like morphology at passage 20 (Fig. 2F). In contrast, only 10 of 25 late MEF iPS  clones 
maintained ES cell-like morphology (Fig. 2F). I also observed that 17 of 18 early TTF iPS 
clones maintained their morphology during 20 passages, whereas only nine of 22 late TTF 
iPS clones maintained their morphology (Fig. 2G). Furthermore, RT-PCR showed that the 
expression levels of Oct4 and Nanog, pluripotency markers, in the non-ES-like clones were 
lower than those in ES cells (Fig. 2H). These data indicate that early iPS clones are more 
stable than late iPS clones. 
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Figure 2. Stability of iPS cell morphology. (A) Outline of early and late iPS production. Early 
iPS clones (GFP-negative colonies) were picked on days 13, 12. 14.  12,  11, and 14 in experiments 
number 181, 191, 197, 185. 195. and 199, respectively. Late  iPS clones (GFP-negative colonies) 
were picked on days 30, 34.  31,  31, 34. and 29 in experiments number  181,  191, 197, 185, 195, and 
 199, respectively. (B-E) Morphology of clones expanded. (B) ES-like early MEF  iPS (clones 
181-2 and 191-5) and late MEF  iPS (clones 181-101 and 191-111). (C) Non-ES-like early MEF  iPS 
(181-5 and  191-I) and late MEF  iPS (clones 181-105 and 197-132). (D) ES-like early TTF  iPS 
(clones  185-11 and 195-15) and late TTF iPS (clones  185-151 and 195-161). (E) Non-ES-like early 
TTF iPS (clone 199-6) and late TTF iPS (clones  185-155, 195-167, and 199-173). (F. G) Stability in 
morphology of MEF and TTF iPS clones. The ratio at passage 20 was obtained by dividing the 
number of ES-like clones by the total number of clones expanded (error bars indicate standard 
 deviations;  *p =  0.058;  "p < 0.01). (H) RT-PCR. Oct4 and  Natiog expression of non-ES-like 
clones derived from MEFs and from adult TTFs was examined. 
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Table 1. Establishment of iPS clones
Experiment
number
Origin
Days of
retroviral silencing
Picked up
colonies
ES-like clones
at passage 10
ES-like clones
at passage 20
181
MEF
13 9 8 7
30 8 4 4
191
12 10 8 8
34 8 6 5
197
14 6 6 6
31 9 6  1
185
TTF
12 6 6 6
31 6 5 3
195
11 6 6 6
34 9 7 3
199
14 6 6 5
29 7 6 3
Similarity of iPS clones with ES cells 
      I next analyzed the proliferation rates and gene expression levels in the early and 
late iPS clones that maintained ES cell-like morphology. From four independent 
experiments (181, 191, 185, and 195), I randomly selected 24 clones: six early MEF iPS 
(clones 181-1, -2, and -3; 191-5, -7, and -9), six late MEF iPS (clones 181-101, -102, and 
-103; 191-111, -113, and -115), six early TTF iPS (clones 185-11, -12, and -13; 195-15, -16, 
and -17), and six late TTF iPS (clones 185-151, -152, and -153; 195-161, -162, and -163). I 
seeded 1 x  105 cells of each iPS clone at passage 16 into a well of a six-well plate with feeder 
cells and expanded the cultures every two days. Most of these clones showed proliferation 
efficiency similar to that of ES cells (Fig. 3 and Table 2). Only one late TTF iPS clone 
(195-163) showed a longer doubling time (Table 2), suggesting that this clone is not a 
superior iPS line. 
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Figure 3. Proliferation of  iPS clones. 
Each iPS clone at passage 16 was seeded into a well of a six-well plate with feeders (day 0) and 
expanded every two days. Shown are representative  iPS (clones  181-1 and  185-151)  and ES cells.
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Table 2. Doubling times of iPS clones
Clone
number
Origin
Timing of
retroviral silencing
Doubling
times (h)
 181-1
MEF
Early
14.3
 181-2 13.9
181-3 14.7
 181-101
Late
14.3
 181-102 14.9
 181-103 14.3
191-5
Early
14.5
191-7 14.5
 191-9 14.1
191-111
Late
14.3
191-113 14.2
191-115 14.0
185-11
TTF
Early
14.5
185-12 14.4
185-13 14.5
 185-151
Late
14.1
185-152 14.4
 185-153 14.4
195-15
Early
14.8
195-16 14.4
195-17 14.3
195-161
Late
14.2
195-162 14.7
195-163 18.3
ES cells 14.2
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      RT-PCR at passage 20 confirmed that the remaining 23 clones expressed 
pluripotency marker genes at comparable levels to those in ES cells and underwent retroviral 
silencing (Fig. 4A). Immunofluorescence analysis confirmed that the 23 clones expressed 
Oct4 and Nanog (Fig. 4B). Furthermore, subclones of the 23 iPS clones at passage 20 were 
positive for alkaline phosphatase, a marker of ES cells (Fig. 4C). These results show that 12 
of 12 early iPS and 11 of 12 late iPS clones at passage 20 are similar to ES cells regarding 
proliferation efficiency and pluripotency marker expression. 
      A recent report showed the nuclear import of Oct4 and Sox2 by Kpnal (also called 
Importin alpha 5 or  Npi  1), Kpna2 (also called Importin alpha 1 or Rchl), and Kpna4 (also 
called Importin alpha 3 or  Qipl) [47]. Another group reported that Exportin 4 was one of 
nuclear transport receptors of Sox2 [48]. Based on these studies, I examined whether there 
were differences in nuclear transport factors expression among the 23 clones. RT-PCR 
showed that expression levels of  Kpnal, Kpna2, Kpna4, Exportin  1 (also called  Crml), 
Exportin 4, and Exportin 5 in the 23 clones were comparable to those in ES cells (Fig. 4A). 
This provides a possibility that the efficiency of nuclear import of Oct4 and Sox2 in my early 
and late iPS clones might be similar to those in ES cells. 
                           24
A
 MEF TTF
 E131  L181  E191  L191  E  185  L  185
 Oct4-enao 
 Oct4-exo 
 Sox2-endo 
 Sox2-exo 
 Kif4-endo 
 K/f4-exo 
 c-Myc-endo 
 c-Mye-exo 
 Nanag 
 Rex-1 
   Kpnal 
 Kpna2 
   Kpna4 
 Expottn 
 Export/n 
 Exportin 5 
   G3pdh
 RT minus
 f 2 3 ' 162 j.l  r, 7  c; ' ' ' C•3 4"."_:1112 17 62 C1:   
,^^• . IMO IMO 41W inp)6 IMP vow 41•111t
 E1.95   _195 
  1'6  162 S
 25
Early MEF  iPS-181-2 Late  TTF  iPS-185-152
 C
Without staining
Early MEF  iPS-181-1 Feeder cells
Figure 4. ES cell marker expression of iPS clones at passage 20. 
(A) RT-PCR. Total RNA was extracted from six early MEF  iPS (clones 181-1, -2, and -3; 191-5, -7, 
and -9), six late MEF iPS (clones 181-101, -102, and -103; 191-111, -113, and -115), six early TTF 
 iPS (clones 185-11, -12, and -13; 195-15, -16, and -17), five late TTF iPS (clones 185-151, -152, and 
-153; 195-161 and -162), and ES cells. The expression of ES cell marker genes (Oct4, Sox2, K1f4, 
c-Myc, Nanog, and  Rex  1), retroviral transgenes, and nuclear transport factors (Kpna and Exportin) was 
examined. (B)  Immunofluorescence. The expression of Oct4 and Nanog was analyzed. Phase 
and fluorescence microscopy images of representative iPS (clones  181-2 and 185-152) are shown. 
(C) Alkaline phophatase staining. iPS clones  (1x105 cells) at passage 20 were seeded into a well of a 
six-well plate with feeders. Two days later, the cells were photographed (top) and stained for 
alkaline phophatase (bottom). A representative iPS clone (early MEF  iPS-181-1) and feeder cells are 
shown
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Chromosomal stability of  iPS clones 
       I next examined the chromosomal stability of the 12 early  iPS and  11 late  iPS clones 
by karyotyping (Fig.  5A, Table  3, and Supplementary Fig.  1). The results at passage 3 
showed that there was no significant difference in the ratio of cells with a normal karyotype 
between early and late MEF iPS clones (p  =  0.19, Fig.  5B) and between early and late TTF  
i  PS clones (p  =0.67  ,  Fig.  5D).  In contrast, at passage 20, the ratio  (18-36%) observed in late 
MEF iPS clones was lower than that  (45-86%) in early MEF  iPS clones (p <  0.01, Fig. 5C). 
Similarly, at passage 20, the ratio  (18-55%) observed in late TTF iPS clones was lower than 
that (55-100%) in early TTF iPS clones (p < 0.01, Fig.  5E). These data demonstrate that 
early iPS clones are more stable than late iPS clones. 
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Figure 5. Chromosomal stability of iPS cells. 
(A) Normal karyotype of 40 chromosomes (left) and abnormality of 42 chromosomes (right) are 
shown. (B—D) The ratio of iPS cells with a normal karyotype was calculated (error bars indicate s.d.). 
(B) Six early MEF iPS and six late MEF iPS clones at passage 3 were examined (p = 0.19). (C) Six 
early MEF iPS and six late MEF iPS clones at passage 20 were examined (**p  <  0.01). (D) Six early 
TTF iPS and five late TTF iPS clones at passage 3 were examined (p = 0.67). (E) Six early TTF iPS 
and five late TTF iPS clones at passage 20 were examined (**p  <  0.01).
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Table 3. Data for karyotyping
Clone
number
Origin
Timing of
retroviral silencing
% Ratio of cells with
a normal karyotype (P3)
% Ratio of cells with
a normal karyotype (P20)
181-1
MEF
Early
100 86
181-2 86 86
181-3 86 86
 181-101
Late
86 27
181-102 45 36
181-103 71 18
191-5
Early
71 71
191-7 86 86
191-9 55 45
191-111
Late
86 18
191-113 71 36
191-115 36 18
185-11
TTF
Early
100 100
185-12 86 71
185-13 86 86
185-151
Late
86 45
 185-152 100 55
185-153 86 18
195-15
Early
86 86
195-16 71 55
195-17 71 71
195-161
Late
55 45
195-162 71 36
 ES cells (P26)  1 86 
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Pluripotency of iPS clones 
      I next evaluated the developmental potential of early iPS clones. I used 10 of the 
12 early iPS clones at passage 20, but excluded clones 191-9 and 195-16, because the ratio of 
cells with a normal karyotype was less than 60% in these clones (Table 3). We injected 
early iPS cells into eight-cell-stage embryos or blastocysts derived from ICR mice. We 
cultured the eight-cell-stage embryos until the blastocyst stage and then transplanted the 
blastocysts into pseudo-pregnant ICR females. We obtained chimeric mice from all of the 
early iPS clones injected (Fig. 6A and Table 4). Polymerase chain reaction (PCR) analysis 
confirmed viral integration i these chimeric mice (Fig. 6B), indicating iPS cell contribution. 
      I crossed male chimeras derived from all 10 different iPS clones with ICR females. 
I obtained viable offspring with black or agouti coat color from chimeras derived from four of 
five early MEF iPS clones and one of five early TTF iPS clones (Fig. 7A and Table 4). PCR 
analysis detected transgene integration i the offspring (Fig. 7B). These results uggest that 
MEFs are more amenable to full reprogramming than adult TTFs. Taken together, my 
results indicate that stable and germline transmittable iPS cells can be efficiently generated by 
establishing ES cell-like colonies undergoing retroviral silencing at earlier time points. 
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A
Early MEF  IPS-191-5  Early TTF  i  PS-1  85-1  1
B
 Chimera
 Oct4-exo 
 Sox2-exo 
 K1f4-exc 
 c-Myc-exo
Figure 6. iPS-derived chimeric mice. 
(A)  Chimeras generated from clones early MEF iPS-191-5 and early TTF  iPS-185-11 are shown. 
The arrow indicates a chimera with chimerism of greater than 90% (left  panel), which was produced 
by eight-cell-stage embryo injection. (B) PCR  genotyping. Genomic DNA was extracted from 
chimeras derived from iPS cells (clones  181-1,  -2. and -3: 191-5 and -7:  185-11.  -12. and  -13:  195-15 
and -17) and an ICR mouse. DNA of the chimera derived from  iPS-102A5 in our  previous report 
was used as a control. Retroviral integration of the four factors was analyzed. 
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A
Early MEF  iPS-181-1 Early MEF  iPS-191-5
B
Oct4-exo 
 Klf4-exo
Figure 7. Germline transmittable iPS cells. 
(A) Coat colors of  F, mice born from  iPS-181-1- and iPS-191-5-derived chimeras crossed with 
wild-type ICR females. The arrow indicates the ICR mother (right panel). 
(B) Genotyping. DNA was isolated from  F, mice (two black and two agouti mice derived from 
 iPS-181-1 and five agouti mice derived from iPS-191-5) and the ICR mother. Viral copies of 0(14 
and K1f4 were examined.
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Table 4. Data for chimera generations
Clone 
number
Origin
  Timing of 
retroviral silencing
Injected 
blastocysts
Injected 8-cell-
stage embryos
Births Adult chimeras
 Chimerism 
10-90%  >  90%
 Germline 
 transmission•
 181-1 
181-2 
181-3 
 191-5 
191-7 
185-11 
185-12 
185-13 
195-15 
 195-17
MEF 
MEF 
MEF 
MEF 
MEF 
TTF 
TTF 
TTF 
 TTF 
 TTF
Early 
Early 
Early 
Early 
Early 
Early 
Early 
Early 
Early 
Early
60 
60 
60 
60 
60 
60 
60 
60 
60 
60
20 
20 
20 
20 
20 
20 
20 
20 
20 
20
33 
6 
29 
2 
20 
5 
31 
8 
27 
0 
37 
2 
22 
11 
27 
2 
25 
0 
35 
2
14 
1 
12 
1 
1 
0 
12 
7 
11 
0 
13 
0 
5 
7 
9 
1 
5 
0 
2 
0
14 
1 
12 
0 
1 
0 
12 
5 
11 
0 
13 
0 
5 
7 
9 
1 
5 
0 
2 
0
0 
0 
0 
1 
0 
0 
0 
2 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0
62/64 
10/15 
25/51 
 N.D. 
 N.D. 
 0 
 12/61 
30/60 
19/87 
 0 
2/113 
 0 
N.D. 
 N.D. 
 N.D. 
 N.D. 
 N.D. 
 0 
N.D. 
 0
* iPS -derived  F, mice/total offspring; N.D., not determined.
Timing of retroviral silencing of individual factors 
      I next analyzed the sequence of retroviral silencing of individual genes in MEF iPS 
cell derivation. First, I examined whether primary colonies express endogenous Oct4, as 
described by other reports [20, 21]. On day 14, I picked three ES cell-like colonies (clones 
128-1, -2, and -3) produced by the four retroviruses. I used half of one colony for RT-PCR 
and expanded the remaining half. RT-PCR at passage 0 showed that two of the three clones 
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expressed endogenous  Oct4 at a comparable level to that in ES cells (Fig. 8A). At passage 
10, the two clones (128-2 and -3) were similar to ES cells in terms of morphology, 
proliferation efficiency, ES marker expression, and karyotype (Fig. 8B—D). Furthermore, 
We generated viable F1 mice using the two clones (Fig. 8E). These data indicate that 
endogenous Oct4 activation can be used as a marker of germline transmittable iPS cells, 
which is consistent with a previous report 1211.
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Figure 8. Germline transmittable  iPS cells selected by endogenous Oct4 expression. 
(A) RT-PCR. Total RNA was extracted from primary iPS colonies (128-1, -2, and -3) and ES cells. 
(B) Morphology of iPS clones (128-2 and -3) at passage 10. (C) Proliferation efficiency and ratio of 
cells with a normal karyotye. (D) Immunofluorescence. Theexpressions of Oct4 and Nanog were 
examined. (E)  F, mice derived from iPS-128-2 and -3. 
      I then picked six ES cell-like coloniesoneach day from day 7 to day 11 (Fig. 9A). 
On day 7, RT-PCR at passage 0 showed that endogenous Oct4 was not detectable in the six 
colonies (Fig. 9B). On days 8 and 9, among the 12 colonies, four colonies (224-5, -7, -8, 
and -9) expressed endogenous  Oct4, whereas the other eight colonies did not, and none of the 
colonies silenced all four retroviral transgenes (Fig. 9C). On days 10 and 11, among the 12 
colonies, four colonies (223-10 and -15; 224-13 and -15) lost the expression of all of the 
transgenes, while six colonies (223-11, -12, -13, and -14; 224-10 and -11) still expressed all 
of the transgenes, and these 10 colonies expressed endogenous Oct4 (Fig. 9D). In addition, 
the other two colonies (224-12 and -14) did not express endogenous Oct4, and still expressed 
all of the transgenes. These results imply that retroviral silencing of all of the factors 
proceeds almost simultaneously during MEF reprogramming in colonies undergoing silencing 
at early time points. 
       I also examined expression levels of Kpnal ,  Kpna2, Kpna4, Exportin 1, Exportin 4, 
and Exportin  5 in the colonies picked on days 8-11. All of the colonies expressed these 
nuclear transport factors at levels similar to those in ES cells (Fig. 9C and D). My data 
suggest hat variations in Oct4, Sox2, and Nanog expression and retroviral silencing of the 
different colonies may not be caused by abnormality of nuclear transport signals. 
Understanding of how retroviral genes are almost simultaneously silenced is valuable to the 
field, and therefore I will continue to analyze it in a further study. 
                           35
A 223-1 (day 7) 224-5 (day 8)  224-7 (day 9) 223-10 (day 10) 224-13  (day 11)
Day 7
 223-
Oct4-enOo 
 Sox2-endo 
  Nanog 
  G3pdh 
RT  rni%s
 1  2  3
 224- 
               ru 
1 2 3
C Day  8 Day 9
223- 224-
(r)m
w
223- 224-
4 5 6 4 5 6
0c14-endo 
 Sox2-enOo 
 Nanog 
Oct4-exo 
Sox2-exo 
 K1f4-exo 
c-Myc-exo 
 Kpnal 
 Kpna2 
 Kpna4 
Exportin  I 
 Exportin 4 
 Exportin 5 
 G3pdh 
RT  mi%s
 7  8  9  7  8  9
    4—) 
cf) cia
36
 Day Day 1
 223- 224-
Lc) -2
223- 224-
1C  11  12  1C 11  12
 Octl-enCo 
 Sox2-encc 
 Nanog 
 Oct4-exo 
 Sox2-exo 
c-Myc-exc 
 Konai 
 Kp.r?a2 
 Kona4 
 Exportin 
 Ex  porti  rr 4 
 Expo  tin .5 
 RT
13  1.1  1G 13  14  15
CiD
  ammo 
     •^•• Aoestko• 'amp. 
 - ---  - 
          WOW ..0.10. *me ..^••Eb 
          •••••• .^ar. +eV,
Figure 9. Retroviral silencing of individual factors and gene expression. 
(A) Morphology of ES cell-like colonies generated from MEFs on days 7-11. 
(B—D) RT-PCR. Total RNA was isolated from primary ES cell-like colonies (passage 0) and ES 
cells. The expression of ES cell marker genes, retroviral  transgenes, and nuclear transport factors 
was analyzed.
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Discussion 
      I demonstrate here that early iPS cells produced from both MEFs and adult TTFs 
are more stable than late iPS cells  (Fig.10), when retroviral silencing is used as a criterion of 
iPS cells. Most of the early iPS clones maintained ES cell-like morphology and a normal 
karyotype at high rate during 20 passages. In addition, these lines expressed pluripotency 
marker genes at levels comparable to those in ES cells and proliferated efficiently like ES 
cells. Furthermore, I successfully generated adult chimeras from all early iPS clones 
injected. In contrast, late iPS clones tended to lose their ES cell-like morphology and 
chromosomal stability by passage 20. These data suggest that early completion of 
reprogramming is a crucial factor in stable iPS cell derivation, and that long-term expression 
of the retroviral transgenes during reprogramming might cause the resulting iPS cells to be 
unstable, at least in mouse. Although I used retroviral silencing as a pluripotency marker in 
this study, selection for Oct4, Nanog, or Sox2 protein activation can also be used to establish 
superior iPS cells. It is currently known that the expression of these endogenous marker 
genes correlates with retroviral silencing in primary ES-like colonies [40,  41]. Therefore, 
when the selection markers are utilized, stable iPS cells may be obtained by establishing 
ES-like colonies expressing the markers at earlier time points. It is important o examine the 
stability of mouse and human iPS cells generated with other reprogramming methods that do 
not alter the host genome, such as adenoviruses [34, 35], plasmid vectors [36], and 
recombinant proteins  [37,  38]. 
       I found that my early MEF iPS clones showed germline competency at an 
efficiency of 80% (four of five clones tested, Table 4). This implies that early completion of 
reprogramming may be an important determinant of germline transmission of MEF iPS cells. 
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It is possible that the appropriate culture conditions, which we have previously reported [42], 
may allow for the efficient generation of germline transmittable MEF iPS cells. In the case 
of TTF iPS cells, however, only one clone showed germline contribution and the number of 
iPS-derived offspring was very low (Table 4). Furthermore, I did not observe high 
chimerism in TTF iPS-derived chimeric mice, whereas chimerism of greater than 90% was 
seen in MEF iPS-derived chimeras (Fig. 6A and Table 4). This suggests that the efficiency 
of generating ermline transmittable iPS cells may be influenced by donor cell type and that 
undefined factors, which diminish the differentiation ability of pluripotent cells, may exist in 
TTFs or TTF iPS cells. Alternatively, the genetic background of donor cells or 
reprogramming methods may affect the characteristics of iPS cells, given that the 
developmental potential of adult somatic cell-derived iPS cells has been reported to be 
comparable to that of ES cells  [34,49,50]. 
       It is believed that germline transmission is one of the most stringent ests for the 
pluripotency of mouse iPS cells. Hence, I evaluated my iPS clones by germline 
transmission in addition to the criteria of morphology, proliferation efficiency, ES marker 
expression, and karyotype. My results indicated that there was a variation in germline 
competence of the 10 iPS clones (Table 4), although I did not observe remarkable difference 
in quality among these clones by in vitro criteria. This means that it is crucial to evaluate 
mouse iPS clones by germline transmission in order to examine whether produced clones are 
fully reprogrammed. Furthermore, the criterion of retroviral silencing might have a 
limitation in full reprogramming of adult TTFs. In the case of human iPS cells, germline 
transmission cannot be tested because of ethical problems, and therefore it is hard to clearly 
demonstrate full reprogramming of human somatic cells. However, when human iPS cells 
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        are used for in vitro applications, such as drug screening and disease modeling, it is sufficient 
       for the resulting cells to self-renew and produce useful progeny 1511. Thus, it should be 
        noted that evaluation methods for iPS cells may be flexibly considered according to the
        purpose of study. 
              Althoughit remains to be determined whether my early MEF and TTF iPS cells can 
        produce full-term embryos and mice by tetraploid complementation, as reported by others
        152-541, and whether established early iPS cells can maintain pluripotency in prolonged 
       culture of more than 20 passages, this study develops a method for inducing stable and 
       germline transmittable iPS cells, and will be an important step towards optimizing the
       technology for efficient generation of iPS cells that can be available for in vitro and in vivo
        medical applications.
Figure 10. Correlation of the timing of retroviral silencing with the quality of iPS cells . 
The lack of exogenous GFP expression reflects the silencing of retroviral  Oct4 , Sox2,  Klf4, and c-Myc. 
Retroviral silencing on day 14 allows for the efficient selection of stable iPS cells . 
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Supplementary Figure 1. Number of chromosomes in  iPS clones. 
(A-D) Normal karyotype of 40 chromosomes and abnormality  (38,  39,  41, or 42 chromosomes) were 
 detected.
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